Filtered By:
Procedure: Hemodialysis
Countries: Japan Health
This page shows you your search results in order of date.
Order by Relevance | Date
Total 246 results found since Jan 2013.
Efficacy and Safety of Upacicalcet in Hemodialysis Patients with Secondary Hyperparathyroidism: A Randomized Placebo-Controlled Trial
CONCLUSIONS: Upacicalcet, a novel injectable calcimimetic, is effective and safe for secondary hyperparathyroidism patients receiving HD.CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Phase 3 Study of SK-1403, NCT03801980.PMID:37696667 | DOI:10.2215/CJN.0000000000000253
Source: Clinical Journal of the American Society of Nephrology : CJASN - September 11, 2023 Category: Urology & Nephrology Authors: Takashi Shigematsu Fumihiko Koiwa Yoshitaka Isaka Masafumi Fukagawa Keiko Hagita Yukihisa S Watanabe Daisuke Honda Tadao Akizawa Source Type: research
Influence of blood pressure variations during hemodialysis on the prognosis of dialysis patients
Clin Exp Hypertens. 2023 Dec 31;45(1):2236336. doi: 10.1080/10641963.2023.2236336.ABSTRACTThe prognosis of dialysis patients is poorer than that of the general population. The relationship between dialysis patients' blood pressure (BP) and mortality is controversial. We investigated the relationships between mortality and (i) pre-dialysis BP and (ii) BP variation during hemodialysis in maintenance dialysis patients.We retroactively analyzed the cases of the 284 patients on hemodialysis (mean age 68 ± 13 years old) who had been regularly followed at Kokura Daiichi Hospital, Japan in 2018. We assessed the relationship betwe...
Source: Clinical and Experimental Hypertension - July 28, 2023 Category: Cardiology Authors: Yuko Ohta Masayo Fukuhara Ritsuko Fujisawa Maki Kanesaki Hiroshi Tsuruta Hidetoshi Nakamura Yuhei Kawano Source Type: research
Withdrawal from Hemodialysis in a Patient with IgD Type Multiple Myeloma: A Case-based Review
Acta Med Okayama. 2023 Apr;77(2):221-225. doi: 10.18926/AMO/65154.ABSTRACTSeveral previous case reports have shown that patients with immunoglobulin D (IgD) multiple myeloma (MM) can be withdrawn from hemodialysis, however, the characteristics that can predict withdrawal in these patients have not yet been elucidated. A 57-year-old Japanese woman required hemodialysis because of renal dysfunction due to IgD-λ and Bence Jones protein-λ MM. Bortezomib-based chemotherapy nine days after admission led to her withdrawal from hemodialysis on Day 50. In our case-based review, younger age and early initiation of bortezomib-based...
Source: Acta Med Okayama - April 24, 2023 Category: Universities & Medical Training Authors: Hiroki Iriyoshi Ken-Ei Sada Atsushi Miyauchi Hirotaka Yamamoto Daisuke Hashimoto Shigeru Nojima Shingo Yamanaka Masafumi Kawamura Satoshi Oka Source Type: research
